Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increa... (weeks through 4 years of age (prior to f...)

Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increased Supply

Date:6/25/2009

weeks through 4 years of age (prior to fifth birthday).

The most common local and systemic adverse reactions to Pentacel vaccine include injection site redness, swelling, and tenderness; fever, fussiness, and crying. Other adverse reactions may occur. Known systemic hypersensitivity reaction to any component of Pentacel vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances are contraindications to vaccination.

The decision to give Pentacel vaccine should be based on the potential benefits and risks; if Guillain-Barre syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or if adverse events have occurred in temporal relation to receipt of pertussis-containing vaccine. Encephalopathy within 7 days of administration of a previous dose of a pertussis-containing vaccine or a progressive neurologic disorder is a contraindication. Vaccination with Pentacel vaccine may not protect all individuals. Before administering Pentacel vaccine, please see full Prescribing Information. The full Prescribing Information for Pentacel vaccine is available with the product and on www.pentacel.com and www.vaccineshoppe.com.

About ActHIB Vaccine

ActHIB vaccine is indicated for the active immunization of infants and children 2 through 18 months of age for prevention of invasive Haemophilus influenzae type b disease. The most common local and systemic adverse reactions to ActHIB vaccine include injection site erythema, swelling, and tenderness; fever irritability, drowsiness, and anorexia. Other adverse reactions may occur. ActHIB vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. The decision to give ActHIB vaccine should be based o
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
3. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
4. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
6. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
7. Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
8. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
9. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
10. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season
11. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes

Post Your Comments:

Sanofi Pasteur Responds to Nation's Need for Hib Vaccine With Increa...(weeks through 4 years of age (prior to f...)